Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.51 |
| ▸ | NSD2 | O96028 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | RECQL | P46063 | 2/20 | 0.51 |
| ▸ | CASP6 | P55212 | 2/20 | 0.51 |
| ▸ | APEX1 | P27695 | 1/20 | 0.51 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.51 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.51 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19470796 | 0.91 | RAPGEF4 (0.46) | ALDH1A1TDP1POLBL3MBTL1NSD2 | |
| SCHEMBL19470800 | 0.89 | RAPGEF4 (0.49) | ALDH1A1TDP1POLBL3MBTL1NSD2 | |
| SCHEMBL19470808 | 0.88 | ALDH1A1 (0.50) | ALDH1A1TDP1POLBL3MBTL1NSD2 | |
| SCHEMBL9449481 | 0.86 | ALDH1A1 (0.55) | ALDH1A1TDP1POLBL3MBTL1NSD2 | |
| SCHEMBL11743126 | 0.85 | ALDH1A1 (0.47) | ALDH1A1TDP1POLBL3MBTL1NSD2 | |
| SCHEMBL9082450 | 0.85 | RAPGEF4 (0.50) | ALDH1A1TDP1POLBL3MBTL1NSD2 | |
| SCHEMBL7572634 | 0.84 | ALDH1A1 (0.57) | ALDH1A1TDP1POLBL3MBTL1NSD2 | |
| SCHEMBL30687380 | 0.84 | NPC1 (0.46) | ALDH1A1TDP1POLBNSD2PTGDR2 | |
| SCHEMBL8023017 | 0.84 | NPC1 (0.46) | ALDH1A1TDP1POLBNSD2PTGDR2 | |
| SCHEMBL31302025 | 0.83 | ALDH1A1 (0.54) | ALDH1A1TDP1POLBL3MBTL1NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883715-B2 | Biocompatible polymers, process for their preparation and compositions containing them | BARRITAULT DENIS (FR) | 2014-11-11 | — | — | US | disclosed |
| US-20130287725-A1 | BIOCOMPATIBLE POLYMERS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | BARRITAULT DENIS (FR) | 2013-10-31 | — | — | US | disclosed |
| US-8476220-B2 | Biocompatible polymers, process for their preparation and compositions containing them | BARRITAULT DENIS (FR) | 2013-07-02 | — | — | US | disclosed |
| US-20110243881-A1 | BIOCOMPATIBLE POLYMERS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | BARRITAULT DENIS | 2011-10-06 | — | — | US | disclosed |
| US-7998922-B2 | Process for treating fibroses with biocompatible polymer | BARRITAULT DENIS | 2011-08-16 | — | — | US | disclosed |
| US-20090012040-A1 | BIOCOMPATIBLE POLYMERS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | BARRITAULT DENIS | 2009-01-08 | — | — | US | disclosed |
| US-20040131583-A1 | Therapy, medical diagnosis; cardiovascular disorders, central nervous system disorders, liver disorders, brain disorders; oxidation resistance | BARRITAULT DENIS (FR) | 2004-07-08 | — | — | US | disclosed |
| US-6689741-B2 | DRUGS, MEDICAL DIAGNOSIS | BARRITAULT DENIS (FR) | 2004-02-10 | — | — | US | disclosed |
| US-20010021758-A1 | Drugs, medical diagnosis | BARRITAULT DENIS (FR) | 2001-09-13 | — | — | US | disclosed |
| US-4891168-A | Process for producing steroid derivatives | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1990-01-02 | — | — | US | disclosed |
| EP-0261656-A1 | A process for producing steroid derivatives | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1988-03-30 | — | — | EP | disclosed |